SirPAD Trial Demonstrates Superior Efficacy of Sirolimus-Coated Balloons in Peripheral Artery Disease Treatment
Key Insights
The SirPAD trial, the world's largest randomized controlled study of sirolimus-coated balloons for peripheral artery disease (search), enrolled 1,252 patients and demonstrated superior outcomes compared to uncoated balloon angioplasty.
MagicTouch PTA (search) sirolimus-coated balloons reduced major adverse limb events to 8.8% versus 15% with uncoated balloons at one year, showing a risk difference of -4.9%.
The academic all-comers trial included nearly 50% of patients with acute or chronic limb-threatening ischemia (search), providing robust clinical evidence for hard outcomes.
The world's largest randomized controlled trial evaluating sirolimus-coated balloons for peripheral artery disease (search) has demonstrated superior clinical outcomes compared to traditional uncoated balloon angioplasty, potentially revolutionizing treatment approaches for this challenging condition. The SirPAD trial results were presented at the ACC 2026 Scientific Sessions and simultaneously published in the New England Journal of Medicine.
Trial Design and Patient Population
The academic SirPAD trial enrolled 1,252 patients with femoropopliteal or below-the-knee peripheral artery disease (search) in an all-comers design, meaning consecutive patients were included without eligibility restrictions related to target-lesion characteristics or PAD (search) stage. This approach led to nearly 50% of enrolled patients having acute or chronic limb-threatening ischemia (search), providing sufficient statistical power to demonstrate superiority for hard clinical outcomes.
Patients were randomized to receive either the sirolimus-coated balloon MagicTouch PTA (search) or any uncoated balloon angioplasty. The trial was presented by Prof. Dr. Stefano Barco from the University Hospital Zurich (search) on behalf of the SirPAD Steering Committee members and investigators.
Primary Outcome Results
The primary outcome of major adverse limb events (MALE), encompassing major unplanned amputations affecting the target limb or target-lesion revascularization for critical ischemia (search), occurred in 8.8% of patients in the sirolimus-coated balloon group versus 15% in the uncoated balloon group at one year. This corresponded to a median unbiased estimate of the risk difference of -4.9%, which was both noninferior and superior in favor of MagicTouch PTA (search).
The study also demonstrated a statistically significant reduction in the composite key secondary endpoint of any unplanned target-limb amputation or any target limb revascularization.
Clinical Significance and Expert Commentary
"We are excited about the primary outcome results of SirPAD. It is one of the very few trials in this field that successfully included an all-comers population," said Principal Investigators Prof. Dr. med. Nils Kucher and Prof. Dr. med. Stefano Barco, co-chairs of the trial. They noted that the inclusion of patients with limb-threatening ischemia (search) provided enough events and statistical power to demonstrate superiority for hard clinical outcomes at one year.
Dr. Manish Doshi, Founder and Managing Director of Concept Medical and inventor of MagicTouch, emphasized the importance of rigorous scientific validation: "SirPAD is an important milestone for the PAD (search) community and for the continued evolution of sirolimus-coated balloon therapy. Seeing MagicTouch PTA (search) evaluated in a large, investigator-led randomized trial and supported by peer-reviewed publication reinforces our belief that meaningful innovation must be validated through rigorous science."
Broader Clinical Evidence
The MagicTouch sirolimus-coated balloon represents the most clinically studied drug-coated balloon, creating substantial clinical evidence in both coronary and peripheral domains. The recently conducted SIRONA RCT in femoropopliteal PAD (search) against Paclitaxel DCBs also confirmed the non-inferiority of MagicTouch PTA (search).
Impact on Treatment Guidelines
The SirPAD trial is being characterized as a gamechanger with data marking a turning point in vascular intervention. With the primary analysis published, there is proof of efficacy that sirolimus drug-coated balloons improve clinical outcomes in an all-comers population, with potential impact on future guidelines and expanding available treatment options for physicians.
The robust clinical evidence from this landmark study positions sirolimus-coated balloons as a future treatment alternative that could significantly influence PAD (search) intervention strategies and patient outcomes.